Reliable non-invasive methods for the evaluation of liver fibrosis are desirable, and the risk factors associated with fibrosis are not fully identified.
Methods
A cross-sectional study of a cohort of 805 HIV–HCV-coinfected patients with active HCV replication, most (95.2%) of whom were intravenous drug users, was conducted. Liver fibrosis was measured by transient elastometry with cutoff values of 7.2 kPa (significant fibrosis), 9.4 kPa (advanced fibrosis) and 14.0 kPa (cirrhosis), and by liver fibrosis indexes (LFI; APRI, Forns and FIB-4). Available liver biopsies were also evaluated.
Results
The prevalences of significant fibrosis, advanced fibrosis and cirrhosis were 55.8%, 38.4% and 23.5%, respectively. A number of parameters were associated both in the univariate and multivariate analyses with each of the diverse fibrosis groups; however, only six of them were predictive of all stages of fibrosis: heavy alcohol intake (odds ratio [OR] 3.37, 95% confidence interval [CI] 2.02–5.59; P<0.001), duration of HCV infection (OR 1.13, 95% CI 1.07–1.19; P<0.001), CDC category C3 (OR 1.80, 95% CI 1.07–3.02; P=0.026), anti-HCV treatment failure (OR 4.37, 95% CI 2.24–8.55; P<0.001), thrombocytopaenia (OR 1.015, 95% CI 1.011–1.019; P<0.001) and increased aspartate aminotransferase (1.006, 95% CI 1.0021–1.010; P=0.004). Furthermore, 53%, 68% and 80% of patients with significant fibrosis, advanced fibrosis and cirrhosis, respectively, had increased measures on at least one of the LFI, with the Forns index being the most sensitive. Area under the receiver operating characteristic curves of elastometry to predict histological fibrosis was 0.83 (95% CI 0.76–0.90), 0.89 (95% CI 0.83–0.95) and 0.87 (95% CI 0.80–0.94) for Metavir score ≥F2, ≥F3 and F4, respectively.
Conclusions
Elastometry constitutes a useful tool in the diagnosis and follow-up of HIV–HCV-coinfected patients. Fibrosis is associated with diverse factors, some of them treatable or preventable, which need to be addressed considering the high prevalence and course of fibrosis in these patients.
References
1.
CastéraL., FornsX., AlbertiA.Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol2008; 48: 835–847.
2.
MorenoS., García-SamaniegoJ., MorenoA.Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat2009; 16: 249–258.
3.
CastéraL.Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat2009; 16: 300–314.
4.
CastéraL., VergniolJ., FoucherJ.Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology2005; 128: 343–350.
5.
ZiolM., Handra-LucaA., KettanehA.Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology2005; 41: 48–54.
6.
de LédinghenV., DouvinC., KettanehA.Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr2006; 41: 175–179.
7.
VergaraS., MacíasJ., RiveroA.The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis2007; 45: 969–974.
8.
CadranelJ.F., RufatP., DegosF.Practices of liver biopsy in France: results of a prospective nationwide survey. Hepatology2000; 32: 477–481.
9.
KirkG.D., AstemborskiJ., MehtaS.H.Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis2009; 48: 963–972.
10.
MacíasJ., RecioE., VispoE.Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. J Hepatol2008; 49: 916–922.
11.
Martin-CarboneroL., de LedinghenV., MorenoA.Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. J Viral Hepat2009; 16: 790–795.
12.
Sánchez-CondeM., Montes-RamírezM.L., MirallesP.Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat2010; 17: 280–286.
13.
de LédinghenV., BarreiroP., FoucherJ.Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat2008; 15: 427–433.
14.
SulkowskiM.S., MehtaS.H., TorbensonM.S.Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS2007; 21: 2209–2216.
15.
VispoE., BarreiroP., Del ValleJ.Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther2009; 14: 187–193.
16.
BrugueraM., FornsX.[Hepatitis C in Spain]. Med Clin (Barc)2006; 127: 113–117. Spanish.
17.
González-GarcíaJ.J., MahilloB., HernándezS.[Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study]. Enferm Infecc Microbiol Clin2005; 23: 340–348. Spanish.
18.
WaiC.T., GreensonJ.K., FontanaR.J.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology2003; 38: 518–526.
19.
FornsX., AmpurdanèsS., LlovetJ.M.Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology2002; 36: 986–992.
20.
Vallet-PichardA., MalletV., NalpasB.FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology2007; 46: 32–36.
21.
BedossaP., PoynardT.An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology1996; 24: 289–293.
22.
SandrinL., FourquetB., HasquenophJ.M.Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol2003; 29: 1705–1713.
23.
Martín-CarboneroL., BenhamouY., PuotiM.Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis2004; 38: 128–133.
24.
BarreiroP., Martín-CarboneroL., NúñezM.Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3. Clin Infect Dis2006; 42: 1032–1039.
25.
BenhamouY., Di MartinoV., BochetM.Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology2001; 34: 283–287.
26.
PinedaJ.A., García-GarcíaJ.A., Aguilar-GuisadoM.Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology2007; 46: 622–630.
27.
HuS.X., KyuloN.L., XiaV.W., HillebrandD.J., HuK.Q.Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients. J Clin Gastroenterol2009; 43: 758–764.
28.
BarreiroP., LabargaP., Martín-CarboneroL.Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. Antivir Ther2006; 11: 869–877.
29.
Bani-SadrF., LapidusN., BedossaP.Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis2008; 46: 768–774.
30.
OgawaE., FurusyoN., ToyodaK., TakeokaH., MaedaS., HayashiJ.The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res2009; 83: 127–134.
31.
VergniolJ., FoucherJ., CastéraL.Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat2009; 16: 132–140.
32.
MacíasJ., BerenguerJ., JapónM.A.Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology2009; 50: 1056–1063.
33.
BochudP.Y., CaiT., OverbeckK.Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol2009; 51: 655–666.
34.
SorianoV., MocroftA., RockstrohJ.Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis2008; 198: 1337–1344.
35.
AranzabalL., CasadoJ.L., MoyaJ.Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis2005; 40: 588–593.
36.
VermaS.HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction?J Antimicrob Chemother2006; 58: 496–501.
37.
MacíasJ., MiraJ.A., López-CortésL.F.Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther2006; 11: 839–846.
38.
BerenguerJ., BellónJ.M., MirallesP.Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis2008; 46: 137–143.
39.
ShaheenA.A., MyersR.P.Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials2008; 9: 43–51.
40.
SorianoV., PuotiM., SulkowskiM.Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel. AIDS2007; 21: 1073–1089.
